产品参数
品 名 货 号 CAS 号 纯 度 规 格 价格 Tocilizumab PHM220223 375823-41-9 99.67% 1 mg ¥2700 5 mg ¥5700
品 名
货 号
CAS 号
纯 度
规 格
价格
Tocilizumab
PHM220223
375823-41-9
99.67%
1 mg
¥2700
5 mg
¥5700
产品简介
Tocilizumab (Anti-Human IL6R, Humanized Antibody) 是一种抗人白细胞介素-6 受体 (IL-6R) 的中和抗体,
可阻止 IL-6 与 IL-6R 的结合,从而抑制经典和反式信号。
Tocilizumab 可用于类风湿性关节炎的相关研究。Tocilizumab 在重症 COVID-19 冠状病毒病方面的研究效果显著。
详细介绍
生物活性 Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4]. IC50 & Target IL-6 体外研究 (In Vitro) Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay[2] Concentration: 1 ng/mL, 10 ng/mL, and 100 ng/mL Incubation Time: 24 hours, 48 hours Result: Inhibited the IL-6R expressed on human-derived HARA-B cells. Cell Cytotoxicity Assay[1] Cell Line: Ba/F3-gp130-IL-6R cells Concentration: 0.001–10000 μg/ml Incubation Time: 2 days Result: Inhibited Ba/F3-gp130-IL-6R cell proliferation. Western Blot Analysis[3] Cell Line: SAS cells Concentration: 1 μM Incubation Time: 6 hours Result: Reduced the phosphorylation of STAT3. RT-PCR[3] Cell Line: SAS cells Concentration: 1-5 μM Incubation Time: 24 hours Result: Reduced VEGF mRNA expression. 体内研究 (In Vivo) Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection; 100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2] Dosage: 1.0 mg/100 μL Administration: Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks Result: Led the volume of each metastatic focus significantly smaller. Animal Model: SCID mice with SAS cells[3] Dosage: 100 μg/mL Administration: Intraperitoneal injection;100 μg/mL; every 48 hours; 20days Result: Suppressed the growth of advanced tumors. CAS 号 375823-41-9 中文名称 托珠单抗 运输条件 Shipping with dry ice. 储存方式 Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4].
IC50 & Target
IL-6
体外研究 (In Vitro)
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[2]
Concentration:
1 ng/mL, 10 ng/mL, and 100 ng/mL
Incubation Time:
24 hours, 48 hours
Result:
Inhibited the IL-6R expressed on human-derived HARA-B cells.
Cell Cytotoxicity Assay[1]
Cell Line:
Ba/F3-gp130-IL-6R cells
0.001–10000 μg/ml
2 days
Inhibited Ba/F3-gp130-IL-6R cell proliferation.
Western Blot Analysis[3]
SAS cells
1 μM
6 hours
Reduced the phosphorylation of STAT3.
RT-PCR[3]
1-5 μM
24 hours
Reduced VEGF mRNA expression.
体内研究 (In Vivo)
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2]. Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection; 100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
Dosage:
1.0 mg/100 μL
Administration:
Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Led the volume of each metastatic focus significantly smaller.
SCID mice with SAS cells[3]
100 μg/mL
Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Suppressed the growth of advanced tumors.
中文名称
托珠单抗
运输条件
Shipping with dry ice.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
销售电话:4006-169-114 技术咨询:020-32290876 客服电话:020-84224925 Email:whiga22@126.com 生产地址:广州国际生物岛螺旋四路1号研发A区第三层302房
粤公网安备 44011202000535号